Table 1.
Baseline characteristics of patients
| Characteristics | Aspirin users (n = 60) | Non-aspirin users (n = 60) | P-value |
|---|---|---|---|
| Age (y) | 67.2 ± 15.5 | 66.0 ± 15.6 | 0.56 |
| Gender (Male/Female) | 48/12 | 48/12 | 1 |
| Underlying liver disease | |||
| TB (≤ 3 mg) | 54 (90%) | 57 (95%) | 0.491 |
| GGT (≤ 75 µ/L) | 34 (56.7%) | 27 (45%) | 0.273 |
| PLT (≤ 100 × 109/L) | 17 (28.3%) | 20 (33.3%) | 0.693 |
| Child-Pugh A | 59 (98.3%) | 59 (98.3%) | 1 |
| HBV infection | 56 (93.3%) | 54 (90%) | 0.764 |
| Anti-HCV positive | 2 (3.3%) | 3 (5.0%) | 1 |
| Cirrhosis | 49 (81.7%) | 48 (80%) | 1 |
| Anti-HBV treatment | 9 (15%) | 15 (25%) | 0.238 |
| Tumor characteristics at initial TACE | |||
| AFP (ng/mL) | 2533.6 ± 10993.6 | 3943.4 ± 12681.3 | 0.43 |
| Tumor size (cm) | 4.5 ± 3.3 | 4.8 ± 3.0 | 0.063 |
| Tumor number (solitary) | 45 (75%) | 47 (78.3%) | 0.662 |
| Vascular invasion | 9 (15%) | 9 (15%) | 1 |
| Metastasis | 0 | 0 | 1 |
| Combined treatment | |||
| Hepatic resection | 12 (19.7%) | 10 (16.4%) | 0.687 |
| TACE number | 2.3 ± 2.3 | 2.5 ± 2.2 | 0.616 |
| RFA | 19 (31.7%) | 21 (35%) | 0.150 |
Abbreviations: TB, total bilirubin; GGT, gamma-glutamyl transferase; PLT, platelet; AFP, alpha-fetoprotein; RFA, radiofrequency ablation.